Ditchcarbon
  • Contact
  1. Organizations
  2. Sorrento Therapeutics, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 11 days ago

Sorrento Therapeutics, Inc.

Company website

Sorrento Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, focuses on the development of innovative therapies for cancer and autoimmune diseases. Founded in 2006, Sorrento has made significant strides in the biotechnology sector, particularly in the fields of immunotherapy and antibody development. The company is renowned for its proprietary antibody platform, which includes unique products such as the COVID-19 therapeutic candidate, COVI-MSC, and various cancer treatment modalities. Sorrento's commitment to advancing healthcare solutions has positioned it as a notable player in the biopharmaceutical industry, with a robust pipeline aimed at addressing unmet medical needs. With operations extending across major regions, Sorrento Therapeutics continues to drive innovation and improve patient outcomes globally.

DitchCarbon Score

How does Sorrento Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

32

Industry Benchmark

Sorrento Therapeutics, Inc.'s score of 25 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

42%

Let us know if this data was useful to you

Sorrento Therapeutics, Inc.'s reported carbon emissions

Sorrento Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that Sorrento Therapeutics may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. In the context of the biotechnology industry, many companies are increasingly adopting science-based targets and sustainability initiatives to mitigate climate change. However, without specific emissions data or reduction commitments, Sorrento Therapeutics appears to be at a nascent stage in its climate strategy. As the industry evolves, it may be beneficial for the company to consider developing measurable climate commitments to align with broader environmental goals.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Sorrento Therapeutics, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Sorrento Therapeutics, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Sorrento Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Byondis B.V.

NL
•
Research and development services (73)
Updated 24 days ago

Zai Lab

CN
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

TESSA

FI
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

TG Therapeutics, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

CN
•
Pharmaceutical Preparation Manufacturing
Updated 30 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251008.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy